Trial Profile
A Phase 1/2a, Open-Label, Multicenter, Dose Escalation Study to Assess the Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) Profile of a Long Acting Recombinant FVIIa (MOD-5014) in Adult Men With Hemophilia A or B
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 21 May 2021
Price :
$35
*
At a glance
- Drugs Factor VIIa-CTP (Primary)
- Indications Haemophilia A; Haemophilia B
- Focus Adverse reactions
- Sponsors OPKO Health
- 10 Jul 2019 Status changed from active, no longer recruiting to completed.
- 03 Jan 2019 Planned End Date changed from 1 Sep 2018 to 1 Apr 2019.
- 03 Jan 2019 Status changed from recruiting to active, no longer recruiting.